Last Updated on April 20, 2022.

This article, podcast or recording is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of Lineage Cell Therapeutics, Inc. (“Lineage”). This article, podcast or recording includes certain information obtained from trade and statistical services, third-party publications, and other sources. Lineage has not independently verified such information and there can be no assurance as to its accuracy. All statements in this article, podcast or recording , other than statements of historical fact, are forward-looking statements within the meaning of federal securities laws. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “would,” “expect,” “plan,” “anticipate,” “strategy,” “designed,” “could,” “can,” “intend,” “believe,” “estimate,” “target,” “potential,” “aim,” “seek,” “continue,” “next steps,” “upcoming,” or the negative of these terms and other similar expressions. Such statements include, but are not limited to, statements relating to the broad potential for Lineage’s regenerative medicine platform and Lineage’s ability to expand the same; the projected timing of milestones of future studies, including their initiation and completion; the projected timing of interactions with the FDA to discuss product designation, manufacturing plans and improvements, and later-stage clinical development; the collaboration and license agreement with Roche and Genentech and activities expected to occur thereunder, its potential success, the milestone and royalty consideration payable to Lineage and Lineage’s planned use of proceeds therefrom; the potential success of other existing partnerships and collaborations, the potential opportunities for the establishment or expansion of strategic partnerships and collaborations and the timing thereof; the potential for Lineage’s investigational allogeneic cell therapies to generate clinical outcomes beyond the reach of traditional methods and provide safe and effective treatment for multiple, diverse serious or life threatening conditions; and cash management and runway.  Forward-looking statements involve risks, uncertainties and assumptions that may cause Lineage’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements in this article, podcast or recording , including risks and uncertainties inherent in Lineage’s business and other risks described in Lineage’s filings with the Securities and Exchange Commission (SEC). Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading “Risk Factors” in Lineage’s periodic reports filed with the SEC, including Lineage’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and its other reports, which are available from the SEC’s website at www.sec.gov. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on the cover of this article, podcast or recording . Lineage undertakes no obligation to update any forward-looking statement to reflect events that occur or circumstances that exist after that date, except as required by law.